Filing Flows

Filing Flows › Companies › Arcturus Therapeutics Holdings › Cash flow

Arcturus Therapeutics Holdings cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$7.0M in Q3 2026 · −$62.4M over twelve months

Operating cash flow−$6.9M
Capital spending−$52K
Free cash flow−$7.0M

Analysis

In Q3 2026, Arcturus Therapeutics Holdings generated −$6.9M of operating cash flow and spent $52K on capital projects, leaving free cash flow of −$7.0M. That is $10.4M more than in Q3 2025 (−$17.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$62.5M; the largest uses were operating cash flow ($62.5M); besides operations, cash came from other financing ($11.9M), shares issued ($66K); the cash balance fell by $50.4M.

Operating cash flow was −$6.9M against net income of −$7.4M. The largest differences: deferred revenue −$5.9M, stock-based pay +$4.0M, payables +$1.4M.

Free cash flow

Arcturus Therapeutics Holdings: free cash flow by quarterArcturus Therapeutics Holdings: free cash flow by quarter−$284KQ4 2024−$35.3MQ1 2025−$5.8MQ2 2025−$17.3MQ3 2025−$16.1MQ4 2025−$19.4MQ1 2026−$19.9MQ2 2026−$7.0MQ3 2026
Operating cash flow less capital spending.
Arcturus Therapeutics Holdings: operating cash flow against capital spendingArcturus Therapeutics Holdings: operating cash flow against capital spendingOperating cash flowCapital spending−$284K$0Q4 2024−$35.1M$137KQ1 2025−$5.8M$0Q2 2025−$17.2M$181KQ3 2025−$16.2M−$88KQ4 2025−$19.4M$0Q1 2026−$19.9M$0Q2 2026−$6.9M$52KQ3 2026
Latest (Q3 2026): Operating cash flow −$6.9M, Capital spending $52K.

Capital allocation, year by year

Arcturus Therapeutics Holdings: where the cash came from (up) and went (down), by fiscal yearArcturus Therapeutics Holdings: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$135MFY2021: Net borrowing $46.6MFY2021: Shares issued $902KFY2021: Capital spending −$3.4M$47.5MFY2021FY2022: Operating cash flow $32.0MFY2022: Net borrowing −$5.0MFY2022: Shares issued $1.7MFY2022: Capital spending −$7.7M$33.7MFY2022FY2023: Operating cash flow −$18.1MFY2023: Net borrowing −$27.4MFY2023: Shares issued $2.7MFY2023: Capital spending −$2.9M$2.7MFY2023FY2024: Operating cash flow −$59.7MFY2024: Shares issued $4.7MFY2024: Capital spending −$648K$4.7MFY2024FY2025: Operating cash flow −$74.3MFY2025: Shares issued $12.8MFY2025: Capital spending −$230K$12.8MFY2025
Over these 5 years operating cash flow totalled −$255M; the largest uses were operating cash flow ($287M) and net borrowing ($32.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$185M
Debtnone
Net cash$185M
Cash runway3.0 years

Arcturus Therapeutics Holdings is burning cash: its operations consume cash, a free cash flow of −$62.4M a year at the current rate against $185M of cash and investments: a runway of about 3.0 years before any new financing.

Where the cash came from and went

Arcturus Therapeutics Holdings: sources (+) and uses (−) of cash, Q3 2026Arcturus Therapeutics Holdings: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$6.9MCash drawn (+) / kept (−)$6.7MOther financing$241KCapital spending−$52KShares issued$50K
Arcturus Therapeutics Holdings: sources (+) and uses (−) of cash, TTM to Q3 2026Arcturus Therapeutics Holdings: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$62.5MCash drawn (+) / kept (−)$50.4MOther financing$11.9MShares issued$66KOther investing$52KCapital spending$36K

From profit to cash

Arcturus Therapeutics Holdings: net income to operating cash flow, Q3 2026Arcturus Therapeutics Holdings: net income to operating cash flow, Q3 2026Net income−$7.4MDepreciation & amortization$600KStock-based pay$4.0MReceivables$564KPayables$1.4MAccrued liabilities−$679KDeferred revenue−$5.9MPrepaid and other assets$536KOperating cash flow−$6.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$6.9M−$52K—$50K$6.7M−$7.0M
Q2 2026−$19.9M———$19.9M−$19.9M
Q1 2026−$19.4M——$16K$19.4M−$19.4M
Q4 2025−$16.2M$88K——$4.5M−$16.1M
Q3 2025−$17.2M−$181K—$640K$16.1M−$17.3M
Q2 2025−$5.8M——$274K$20.5M−$5.8M
Q1 2025−$35.1M−$137K$15.0M$195K$20.1M−$35.3M
Q4 2024−$284K——$134K$150K−$284K

Arcturus Therapeutics Holdings: income statement and cash flow

Arcturus Therapeutics Holdings, Q3 2026: revenue $18.3M (+7% year over year), operating margin -50.2%. The chart follows the revenue to costs, profit and cash.

Arcturus Therapeutics Holdings: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.